Results 181 to 190 of about 914,390 (333)

Inhalability and Bioactivity of Spray‐Dried versus Pressurized Gas eXpanded Liquid Technology‐Processed Yeast Beta‐Glucan Microparticles for Anti‐Fibrotic Therapies

Advanced Healthcare Materials, EarlyView.
PGXTEC) liquid technology is utilized to develop highly respirable yeast beta‐glucan (YBG) microparticles for the treatment of pulmonary fibrosis. Compared to conventionally processed spray‐dried YBG, PGXTEC‐YBG exhibits greatly improved aerodynamic properties, enhanced pro‐fibrotic macrophage uptake, and effective downregulation of pro‐fibrotic ...
Nate Dowdall, Safaa Naiel, Quan Zhou, Pareesa Ali, Tamana Rubina Yousof, Emily Wong, Ricardo Couto, Byron Yépez, Bernhard Seifried, Paul Moquin, Rod Rhem, Myrna Dolovich, Martin Rainer Kolb, Kjetil Ask, Todd Hoare   +14 more
wiley   +1 more source

Lipid Management in the Post-Statin Era: FDA Indications for Bempedoic Acid. [PDF]

JACC Adv
Powell HA, Bloedon L.
europepmc   +1 more source

FDA ‘fails to keep track of transplant patients’ [PDF]

, 1998
Meredith Wadman
openalex   +1 more source

An Innovative “Tooth‐On‐Chip” Microfluidic Device Emulating the Structure and Physiology of the Dental Pulp Tissue

Advanced Healthcare Materials, EarlyView.
This work presents a “tooth‐on‐chip” device that mimics dental pulp tissue. By co‐culturing key cell types, it recreates vascular networks, stem cell niches, the odontoblast/dentine interface, and trigeminal innervation. This innovative platform provides a unique model of dental pulp structure and physiology, with significant potential for accelerating
Alessandro Cordiale, Deborah Stanco, Roberta Visone, Bernd Stadlinger, Pierfrancesco Pagella, Marco Rasponi, Thimios A. Mitsiadis   +6 more
wiley   +1 more source

US adolescents' response to nicotine warning labels in influencer e-cigarette marketing social media posts: a survey-based randomised between-subject experiment. [PDF]

Tob Control
Vassey J, Vogel EA, Unger JB.
europepmc   +1 more source

EC, FDA and Health Canada [PDF]

, 1998
R. Lenkei, G. E. Marti, R. Vogt, J. Nicholson, F. Mandy   +4 more
openalex   +1 more source

FDA research [PDF]

Nature Medicine, 1997
S L, Epstein, B F, Anthony
openaire   +2 more sources

Silencing Myostatin Using In Vivo Self‐Assembled siRNA Protects Against Cancer‐ and Dexamethasone‐Induced Muscle Atrophy

Advanced Healthcare Materials, EarlyView.
This study reports an in vivo self‐assembled siRNA strategy that enables the liver to generate small extracellular vesicles (sEVs) tagged with a muscle‐targeting peptide (MSP) and naturally loaded with myostatin (MSTN)‐siRNA. These MSP‐tagged sEVs are systemically delivered to skeletal muscle, efficiently silence MSTN, promote muscle hypertrophy, and ...
Xin Yin, Azhar Anwar, Jiehao Chen, Qinghao Sun, Likun Zhou, Jie Tang, Jingwei Guo, Linbo Yan, Yongci Chen, Feng Yin, Chen‐Yu Zhang, Zigang Li, Jizheng Ma, Liyuan Sheng, Xi Chen   +14 more
wiley   +1 more source

Long-Term Outcomes of Cervical Disc Replacement and Anterior Cervical Discectomy and Fusion: A Review of FDA IDE Trials With Real-World Comparison. [PDF]

Global Spine J
Issani A, Karakash WJ, Avetisian H, Ahsan Z, Patel D, Riopelle D, Kashanchi K, Gallo M, Hah RJ, Malik AA, Alluri RK, Liu JC, Wang JC.   +12 more
europepmc   +1 more source

Overview of requirements for quality control and assurance in molecular diagnostics transferred to the clinical laboratory and the role of the FDA and USDA in licensing test kits that make this possible

, 1993
A. Bennett Jenson, Stanley J. Geyer
openalex   +1 more source